Fresh Tracks Therapeutics Fresh Tracks Therapeutics Home
  • Company
    • Vision
    • Values
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partner With Us
    • Join Us
  • Scientific Innovations
  • Pipeline
    • Overview
    • FRTX-02
    • FRTX-10
    • Next-Generation Kinase Inhibitors
    • FRTX-03
  • Investor Relations
Main Menu
Contact Us
Investor Relations

News

Investors

Investors

  • Overview
  • News
  • Events
  • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
Mar 08, 2022 4:05pm EST

Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022

Feb 02, 2022 7:30am EST

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

Nov 09, 2021 4:05pm EST

Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 01, 2021 4:05pm EDT

Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021

Oct 28, 2021 7:58am EDT

Brickell Biotech Prices Public Offering of Common Stock

Oct 27, 2021 4:32pm EDT

Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock

Oct 07, 2021 6:55am EDT

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

Sep 17, 2021 8:00am EDT

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

Sep 08, 2021 8:30am EDT

Brickell Biotech to Participate at Upcoming September Conferences

Sep 01, 2021 7:05am EDT

Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next Pagearrow_forward
  • Email Alerts
  • RSS News Feed

Company

  • Vision
  • Values
  • Leadership
  • Partner With Us
  • Join Us

Discover

  • Scientific Innovations
  • Pipeline
  • Investor Relations
  • News
  • Contact Us

Follow Us

  • LinkedIn
  • Twitter
  • Instagram
  • Facebook
  • Compliance
  • Terms of Use
  • Privacy Policy
  • Accessibility
©2023 Fresh Tracks Therapeutics, Inc.

We use first- and third-party cookies to obtain statistical information to personalize our website and provide you with a better experience. If you continue without changing your settings, this demonstrates your consent to receive all cookies or other tracking technologies on the FRTX website for the purposes described in our Privacy Policy. Please know that you can change your cookie settings at any time in your browser settings.

Close